Could Moderna/Merck Cancer Vaccine Succeed Where Others Have Flopped?

 
• By Alaric DeArment

The partners unveiled long-awaited proof-of-concept data for mRNA-4157 at the AACR meeting showing a statistically significant improvement in recurrence-free survival among melanoma patients.

Moderna and Merck unveiled long-awaited data from their Phase IIb study of cancer vaccine mRNA-4157 in melanoma • Source: Shutterstock

More from Immuno-oncology

More from Anticancer